NCT06566560 The ROAD 2.0 to Sustainable Medication Use: Redispensing Unused Oral Anticancer Drugs
| NCT ID | NCT06566560 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Radboud University Medical Center |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2024-01-10 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,500 participants in total. It began in 2024-01-10 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective intervention study is to investigate the effectiveness of redispensing unused oral anticancer drugs. The main questions it aims to answer are: * What are the cost-savings of redispensing unused oral anticancer drugs? * What is the environmental impact of redispensing unused oral anticancer drugs? Researchers will compare redispensing unused oral anticancer drugs to the standard practice of disposal. Participants will receive their oral anticancer drugs in a sealed bag with a temperature indicator if needed. They will be asked to return any unused oral anticancer drugs to the pharmacy during their next visit to the hospital.
Eligibility Criteria
Inclusion Criteria: * Patients of all ages * A clinical diagnosis of cancer using an oral anticancer drug that requires storage at room temperature according to the Summary of Product Characteristics (SmPC). Exclusion Criteria: * Patients that do not understand the Dutch or English language, in written or spoken. * Patients receiving prescriptions that contain an amount of tablets that deviates from the regular package size, resulting in the pharmacy dispensing an opened package
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06566560 clinical trial?
This trial is open to participants of all sexes, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06566560 currently recruiting?
Yes, NCT06566560 is actively recruiting participants. Contact the research team at Shirley.Xie@radboudumc.nl for enrollment information.
Where is the NCT06566560 trial being conducted?
This trial is being conducted at Nijmegen, Netherlands.
Who is sponsoring the NCT06566560 clinical trial?
NCT06566560 is sponsored by Radboud University Medical Center. The trial plans to enroll 2,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.